Lexaria Bioscience Corp. (NasdaqCM: LEXX)
Health Care · Pharmaceuticals · CA
$3.32
+15.28% today · -74.2% 1Y
Lexaria Bioscience Corp. (NasdaqCM: LEXX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.49M and employs 7 people.
Over the last twelve months the share price has lost 74.2%, trading between 2.80 and 21.60.
Tweenvest scores Lexaria Bioscience Corp. across four factors: quality 37/100, value 47/100, growth 100/100. Its strongest factor is growth.
LEXX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.49M
- Revenue (TTM)
- $194.00K
- P/E
- —
- EPS
- -5.14
- Dividend yield
- —
- Beta (5Y)
- 0.60
- 52-week high
- $21.60
- 52-week low
- $2.80
- Avg volume (3M)
- —
- Shares outstanding
- 1.65M
- Employees
- 7
- Next earnings
- —
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
- ISIN
- US52886N6040
- Founded
- 2004
- Listed since
- Jan 12, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Panacea Life Sciences Holdings, Inc.OTCPK: PLSH | $5.78M | $0.09 | +6.25% |
| Invex Therapeutics LtdASX: IXC | $5.77M | AU$0.11 | -4.35% |
| ECS Botanics Holdings LtdASX: ECS | $5.59M | AU$0.01 | -9.09% |
| Lamdong Pharmaceutical Joint Stock CompanyHNX: LDP | $5.50M | ₫7,600.00 | -1.30% |
| Glow Lifetech Corp.CNSX: GLOW | $5.39M | CA$0.04 | -11.11% |
| Pulmatrix, Inc.NasdaqCM: PULM | $5.33M | $1.46 | -7.01% |
| Christina Lake Cannabis Corp.CNSX: CLC | $5.22M | CA$0.03 | +20.00% |
| Q/C Technologies, Inc.NasdaqCM: QCLS | $5.16M | $0.63 | -15.78% |
Figures last refreshed Oct 11, 2026.